Partnership of interest from the world

In brief
Detailed description

Italian University is offering the construction of stable mammalian cell lines hyper-producing recombinant proteins to pharmaceutical companies, universities and research centres.

Proposal reference:TOIT20210719002

Biology and biotechnology department of an Italian University developed an efficient system to produce recombinant proteins in mammalian cells in culture to be used as drugs or for structural biology studies. The University is looking for pharmaceutical companies, universities and research centres, under technical cooperation and research cooperation agreements.

Italian university department of biology and biotechnology is offering the construction of cell lines for the production of recombinant proteins in mammalian cells to be used for structural biology studies. Recombinant proteins are particularly relevant in various fields, from drug production and diagnosis to basic research. The expiration of patents for therapeutic protein drugs opens up opportunities for biosimilars to enter the market since pharmaceutical companies are willing to obtain their own expression systems. The production in mammalian cells, although expensive, is necessary for many proteins whose function is dependent on posttranslational modifications. We developed a mammalian vector-host cell system which allows high production efficiency, thereby decreasing production costs. We offer to the market the construction of stable mammalian cell lines (human or hamster) constitutively expressing any protein of interest. The system is already working very well and has been used successfully for the construction of human and Chinese hamster cell lines hyper-expressing different proteins such as hydroxylase 3 (LH3) and human erythropoietin. The service includes protein characterization through mass spectrometry (MALDI - TOF/TOF), western blotting, quantitative analysis of RNA by RT-PCR, cellular characterization by fluorescent in situ hybridization (FISH) and several additional molecular and cellular biology methods. The University is looking for international partners such as companies, active in the pharmaceutical field, universities and research centres. The types of partnership considered are technical and research cooperation agreements, in order to explore the innovative application, research and development solution on recombinant protein.

Profile reference: TOIT20210719002
Type: Technology Offer
Country: Italy

Submission date: 19/07/2021
Profile updated on: 14/03/2022
Profile valid until: 27/07/2022

Partnership

Development stage	Already on the market
Development stage - comment	The system has been successfully tested in several projects and is ready to be used for new projects. Cell lines hyperproducing biosimilar drugs have been constructed and sold to pharma companies. Cell lines hyperproducing Human Lysyl hydroxylase 3 (LH3) have been used for structural studies. The production and characterization of cell lines hyperproducing other proteins is under way.
Cooperation Ipr Status	Other
Cooperation Ipr Comment
Cooperation Partner Area	Big companies, small and medium enterprises active in the pharmaceutical sector developing biosimilar drugs or any other product for whom recombinant protein are needed both in EU and extra EU. University and research centres developing structural biology studies needing recombinant proteins in mammalian cells. The types of partnership considered are: - technical agreement and research cooperation agreement, in order to explore innovative application and research and development solution on recombinant protein.
Cooperation Partner Sought

Company / Organisation

Organisation type	University
Company Turnover
Company Since	1361
Company Transnational	Si

Technological fields

Attachments

#	File Preview	File name
No results found.